SUMMARY Pulse methylprednisolone therapy has dramatic effects on clinical and immunological parameters of disease activity in patients with rheumatoid arthritis. Previous studies of this treatment have all used the intravenous route and methylprednisolone succinate. This study addresses the question of whether oral prednisolone in equivalent doses can substitute for intravenous methylprednisolone in pulse therapy in a double blind parallel study. It is shown that oral prednisolone has clinical and immunological effects equivalent to those of intravenous methylprednisolone, making it possible to administer pulse therapy to patients with rheumatoid arthritis as outpatients without the inconvenience and inherent dangers of intravenous administration.
Pulse methylprednisolone therapy has been used for several years as a treatment for active synovitis for patients with rheumatoid arthritis (RA). Previous studies have examined the response to conventional doses of oral prednisolone or 'megadoses' of intravenous methylprednisolone, but no studies have considered whether equivalent doses of oral prednisolone would produce the same clinical effects as megadoses of methylprednisolone administered intravenously. We therefore examined the clinical response and side effects resulting from equivalent oral and intravenous doses of corticosteroids in a double blind manner to see whether oral pulse therapy was an effective substitute for intravenous pulse therapy in rheumatoid arthritis.
Patients and methods
Twenty four patients with definite rheumatoid arthritis (American Rheumatism Association criteria) and active joint disease were prospectively entered into the study and randomly assigned to two patient groups. Clinical details of both patient groups are presented in Table 1 (2) (3) (4) (5) (6) 74.9 (9) Analysis of within group effects with time was performed using a multiple analysis of variance and Bonferroni's method for multiple comparisons.
Statistical significance was accepted at the 5% level.
An estimate of the Pi error in the study was made.9
With a 90% response rate in the intravenous methylprednisolone group and a significance of 5%, we would not be able to detect any less than a 35% difference between the two treatment groups in this study. 
Results
There were 12 patients in each treatment group, one group receiving intravenous methylprednisolone and placebo tablets, while the other group received oral prednisolone and intravenous saline. Mean duration of response was 13 weeks in the group receiving the active oral preparation and 13-6 weeks in the group treated with the active intravenous preparation. Two patients in each group had not relapsed at completion of the study and one patient in the active oral preparation group had a duration of response of less than four weeks.
The effects of pulse therapy on the clinical and laboratory parameters of disease activity and on neutrophil and lymphocyte counts and cell surface markers are presented in Figs 1-7 and Tables 2 to 4 .
Analysis of effect of time, within groups, showed significant changes (p<005) in VAS pain and mobility, duration of morning stiffness, grip strength, and articular index up to 16 weeks follow up compared with pretreatment levels in both groups. CRP, immune complexes, IgA, and rheumatoid factor levels were also significantly decreased in both groups up to eight weeks follow up in both groups, but no significant change was seen in either group for IgG and IgM levels or for neutrophil and lymphocyte counts when compared with pretreatment levels. There were no significant 
